No more than 15 authors can be listed.Please ensure the authors are listed in the right order.If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.
Tezepelumab was approved for severe asthma in Japan in 2022, but real-world effectiveness data remain limited. We aimed to identify biomarkers predicting response and to evaluate how discontinuation due to adverse events or other reasons influences treatment assessment.
We prospectively analyzed 65 patients with severe asthma who initiated tezepelumab at 13 institutions (December 2023–October 2024). A 3-WAY responder met all: (1) ACQ-6 ≤ 0.75 or ΔACQ-6 ≤ -0.5, (2) no exacerbations, and (3) no maintenance oral corticosteroids. A 4-WAY responder was a 3-WAY responder additionally meeting %FEV1 ≥ 80% or ΔFEV1 ≥ 100 mL. P < 0.05 was considered significant.
McNemar exact tests showed significant changes in 3-WAY response rates at weeks 24 and 52 versus baseline. Week-52 response was more frequent among those achieving 3-WAY at week 24 (risk difference 46.67 percentage points; 95% CI 16.33–66.74; risk ratio 2.40; 95% CI 1.26–4.57). ANCOVA showed a greater week-24 change in FEV1 in patients with baseline FeNO ≥ 50 ppb. Nineteen patients discontinued during follow-up. Cox models treated discontinuation as censoring and Fine–Gray models treated it as a competing event; Wald Z tests (normal approximation; H0: mean = 0) were applied to baseline values and changes. Older age, smoking history, and baseline eosinophils ≥ 300/μL were significant in both models. Baseline eosinophils were also associated with 4-WAY response; baseline ACT was associated with both 3-WAY and 4-WAY response, whereas ACQ-6 was associated with 3-WAY only. Findings were directionally consistent across alternative competing-risk definitions for discontinuation.
In severe asthma, tezepelumab effectiveness appeared to be associated with baseline eosinophil counts. Older age and a history of smoking may be associated with higher instantaneous and cumulative response. Lung function improvement may also be greater in patients with higher baseline FeNO.